BioMed Research International / 2014 / Article / Tab 1

Research Article

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

Table 1

Patient characteristics between chemotherapy responder and nonresponders.

CharacteristicsResponders%Nonresponders%

Age (years) 0.041
Gender
  Male20756.9%32857.1%0.494
  Female 15743.1%24642.9%
Smoke status
 Nonsmokers8423.1%8915.5%<0.001
 Smoker28076.9%48784.5%
Histology type
  Squamous cell carcinoma 20857.1%32155.9%0.383
  Adenocarcinoma 15642.9%25344.1%
Stage
 IIIA15642.9%18732.6%0.005
 IIIB11932.7%21136.8%
 IV8924.5%17630.7%
Differentiation
 Well13436.8%16528.7%0.019
 Moderate12935.4%21036.6%
 Poor10127.7%19934.7%
Chemotherapy regimens
  DDP/CBP + TAX/TXT/DOC 15642.9%23340.6%0.168
  DDP/CBP + GEM 12133.2%22439.0%
  DDP/CBP + NVB 8723.9%11720.4%

NS: not significance; DDP: cisplatin; CBP: carboplatin; TAX: taxol/paclitaxel; TXT: taxetere; DOC: docetaxel; GEM: gemcitabine; NVB: vinorelbine.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.